Authors: Tall CT, Diack ND, Sow D, Ndiaye N, Lemrabott AT, Leye A.
Introduction: In our low-income countries, very few data are reported on the prescription of gliflozins and GLP1 receptor agonists. The aim of our study was to describe the characteristics of patients treated with these new molecules and to assess their impact on metabolic parameters.
Methodology: We conducted a longitudinal study over a six-month period. Diabetic patients on AR GLP1 or i SGTL2 were included. Socio-demographic data, diabetes-related data, data relating to the molecules evaluated and evolutionary data at 3 and 6 months were collected.
Results: Our cohort comprised 56 patients with a mean age of 64.6 ± 12.1 years. The socioeconomic status of our patients was considered average (85.7%) and high (14.3%). The mean duration of diabetes was 109.7 months ± 50. Our study population consisted of e T2DM patients at very high cardiovascular risk; with associated cardiovascular risk factors (dyslipidemia, hypertension or overweight-obesity) and cardiovascular or renal complications. This justified iSGTL2 or ARGLP1 treatment in accordance with international recommendations. Therapeutically, 46 patients were on iSGLT2 (82.1%) and 10 on AR GLP-1 (17.9%), i.e. a hospital prescription prevalence of 8%. Treatment was adhered to in 91.1% of cases. Progression was marked by a significant improvement in all parameters assessed in both subgroups. Weight reduction and HbA1c reduction were much greater in the AR GLP1 subgroup. The improvement in GFR and CAR was more significant in the iSGLT2 subgroup.
Conclusion: We find that iSGLT2 and AR GLP-1 are highly effective therapeutic agents in terms of glycemic control, weight reduction, control of cardiovascular risk factors and cardiac and renal protection.
View/Download pdf